Cencora Inc. (COR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cencora Inc. (COR) has a cash flow conversion efficiency ratio of 0.373x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.34 Billion) by net assets ($3.58 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Cencora Inc. worth for the company's overall valuation and market capitalisation.
Cencora Inc. - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Cencora Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cencora Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cencora Inc. ranked by their cash flow conversion efficiency. Explore Cencora Inc. (COR) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Corteva Inc
NYSE:CTVA
|
-0.018x |
|
Unimicron Technology Corp
TW:3037
|
0.050x |
|
State Street Corp
NYSE:STT
|
-0.082x |
|
Sandvik AB
ST:SAND
|
0.046x |
|
Nanya Technology Corp
TW:2408
|
-0.006x |
|
HOYA CORP. ADR/ 1 O.N.
F:HYB0
|
N/A |
|
Discover Financial Services
NYSE:DFS
|
0.112x |
|
Roche Holding AG
SW:RO
|
0.195x |
Annual Cash Flow Conversion Efficiency for Cencora Inc. (1994–2025)
The table below shows the annual cash flow conversion efficiency of Cencora Inc. from 1994 to 2025. View current stock price of Cencora Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.75 Billion | $3.88 Billion | 2.218x | -49.92% |
| 2024-09-30 | $786.74 Million | $3.48 Billion | 4.429x | -24.55% |
| 2023-09-30 | $666.29 Million | $3.91 Billion | 5.870x | -84.52% |
| 2022-09-30 | $71.27 Million | $2.70 Billion | 37.926x | +731.19% |
| 2021-09-30 | $584.41 Million | $2.67 Billion | 4.563x | +273.59% |
| 2020-09-30 | $-839.64 Million | $2.21 Billion | -2.629x | -403.40% |
| 2019-09-30 | $2.71 Billion | $2.34 Billion | 0.866x | +65.84% |
| 2018-09-30 | $2.70 Billion | $1.41 Billion | 0.522x | -27.57% |
| 2017-09-30 | $2.06 Billion | $1.49 Billion | 0.721x | -52.77% |
| 2016-09-30 | $2.08 Billion | $3.18 Billion | 1.527x | -84.83% |
| 2015-09-30 | $389.56 Million | $3.92 Billion | 10.064x | +1245.96% |
| 2014-09-30 | $1.96 Billion | $1.46 Billion | 0.748x | +120.07% |
| 2013-09-30 | $2.32 Billion | $788.12 Million | 0.340x | -36.06% |
| 2012-09-30 | $2.46 Billion | $1.31 Billion | 0.531x | +30.43% |
| 2011-09-30 | $2.87 Billion | $1.17 Billion | 0.407x | +8.56% |
| 2010-09-30 | $2.95 Billion | $1.11 Billion | 0.375x | +30.06% |
| 2009-09-30 | $2.72 Billion | $783.76 Million | 0.289x | +6.08% |
| 2008-09-30 | $2.71 Billion | $737.07 Million | 0.272x | -30.21% |
| 2007-09-30 | $3.10 Billion | $1.21 Billion | 0.390x | +99.90% |
| 2006-09-30 | $4.14 Billion | $807.26 Million | 0.195x | -45.34% |
| 2005-09-30 | $4.28 Billion | $1.53 Billion | 0.357x | +87.57% |
| 2004-09-30 | $4.34 Billion | $825.08 Million | 0.190x | +114.65% |
| 2003-09-30 | $4.01 Billion | $354.81 Million | 0.089x | -45.18% |
| 2002-09-30 | $3.32 Billion | $535.93 Million | 0.162x | +1246.68% |
| 2001-09-30 | $2.84 Billion | $-40.00 Million | -0.014x | -101.84% |
| 2000-09-30 | $282.29 Million | $216.58 Million | 0.767x | +4152.92% |
| 1999-09-30 | $166.30 Million | $3.00 Million | 0.018x | -98.92% |
| 1998-09-30 | $75.30 Million | $125.90 Million | 1.672x | +357.09% |
| 1997-09-30 | $14.30 Million | $-9.30 Million | -0.650x | +40.17% |
| 1996-09-30 | $-36.80 Million | $40.00 Million | -1.087x | -514.33% |
| 1995-09-30 | $-135.70 Million | $-35.60 Million | 0.262x | +193.91% |
| 1994-09-30 | $-300.70 Million | $84.00 Million | -0.279x | -- |
About Cencora Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order … Read more